Your session is about to expire
← Back to Search
Cryoablation + Immunotherapy for Early Stage Breast Cancer
Study Summary
This trial is testing whether two cancer treatments, cryoablation and immune therapy, are safe to use together in women with early stage breast cancer.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 30 Patients • NCT04118166Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You have a negative test for HIV.I have cancer in both breasts at the same time.You have a current, known, or suspected autoimmune disease.I regularly take medication to suppress my immune system.My cancer may or may not have spread to my lymph nodes.I haven't received vaccines for infectious diseases in the last 4 weeks.I have previously been treated with drugs targeting the immune system.My tumor is larger than 1.5 cm and can be surgically removed.I have inflammatory breast cancer.Your blood test results need to meet certain standards.You tested negative for Hepatitis B and Hepatitis C.Women who could become pregnant must have a negative pregnancy test within 14 days before starting the medication.My tumor is located more than 5 mm away from the skin.I am scheduled for breast surgery.My tumor can be treated with freezing as decided by a radiologist.I am fully active or can carry out light work.My cancer has not spread to distant parts of my body.I haven't taken any experimental drugs in the last 2 weeks.I haven't had cancer treatment, including surgery or radiation, in the last 2 weeks.My cancer's hormone and HER2 status is currently being tested.My cancer is present in multiple locations within the same organ.My cancer is HER2-positive.I am a woman aged 18 or older.My breast cancer has been confirmed as invasive adenocarcinoma by a pathology test.
- Group 1: Cryoablation and Immune Therapy
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Have any other investigations been conducted pertaining to Cryoablation?
"At present, 763 live clinical trials for Cryoablation are in progress with 87 studies in the third phase. While Pittsburgh, Pennsylvania is home to many of these proceedings, 43517 sites across the world are taking part in Cryoablation research."
What medical maladies does Cryoablation typically address?
"Cryoablation is a technique used to combat the effects of anti-angiogenic treatment and can be employed in cases ranging from malignant neoplasms to unresectable melanoma, as well as squamous cell carcinoma."
How many subjects are participating in the current clinical trial?
"Unfortunately, no further participants are being accepted for this medical study. The clinical trial was listed on June 1st 2016 and the last update occurred on July 1st 2022. For those seeking additional trials, 2601 studies involving breast cancer and 763 Cryoablation-focused experiments are currently in need of patients."
Are there available slots for participants in this trial?
"At the moment, this medical trial is not presently recruiting. It was initially posted on June 1st 2016 and edited on July 1st 2022. For those seeking other studies related to breast cancer, there are currently 2,601 trials admitting patients while 763 clinical trials for cryoablation are actively enrolling participants."
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
Share this study with friends
Copy Link
Messenger